公开(公告)号：DE3612212A1

公开(公告)日：1987-10-15

申请号：DE3612212

申请日：1986-04-11

Applicant: BASF AG

Inventor： GOERTZ HANS-HELMUT DR ,  KLIMESCH ROGER DR ,  LAEMMERHIRT KLAUS DR ,  LANG SIEGFRIED DR ,  SPENGLER REINHARD DR ,  SANNER AXEL DR

IPC: A61K47/32 ,  A61J3/06 ,  A61K9/20 ,  A61K9/22 ,  A61K9/26 ,  A61K47/00 ,  A61J3/00 ,  C08L39/06

Abstract: Process for the preparation of solid pharmaceutical forms by mixing one or more pharmaceutical active compounds with one or more fusible, pharmacologically tolerated binders and, if required, other conventional pharmaceutical auxiliaries, at from 50 DEG to 180 DEG C., and subjecting the mixture to injection molding or extrusion and shaping, wherein the fusible binder used is a NVP polymer which contains not less than 20% by weight of NVP as copolymerized units, and, where they are present, all of whose comonomers contain nitrogen and/or oxygen.

公开(公告)号：ES2115705T3

公开(公告)日：1998-07-01

申请号：ES93117141

申请日：1993-10-22

Applicant: BASF AG

Inventor： HARTH KLAUS DR ,  HIBST HARTMUT DR ,  DEMBOWSKI JUERGEN DR ,  SPENGLER REINHARD DR ,  FLAIG ERNST DR

IPC: A61K9/32 ,  A61K9/22 ,  A61K9/28 ,  A61K9/50 ,  A61K9/52 ,  A61K47/34

公开(公告)号：AT123649T

公开(公告)日：1995-06-15

申请号：AT92119226

申请日：1992-11-11

Applicant: BASF AG

Inventor： MUELLER WINFRIED DR ,  SPENGLER REINHARD DR ,  GRABOWSKI SVEN DR ,  SANNER AXEL DR

IPC: A61K9/20 ,  A61K9/22

公开(公告)号：DE3780059D1

公开(公告)日：1992-08-06

申请号：DE3780059

申请日：1987-03-31

Applicant: BASF AG

Inventor： GOERTZ HANS-HELMUT DR ,  KLIMESCH ROGER GUENTHER DR ,  LAEMMERHIRT KLAUS DR ,  LANG SIEGFRIED DR ,  SANNER AXEL DR ,  SPENGLER REINHARD DR

IPC: A61K47/32 ,  A61J3/06 ,  A61K9/20 ,  A61K9/22 ,  A61K9/26 ,  A61K47/00

Abstract: Prodn. of solid pharmaceutical dosage forms is effected by mixing at least one active ingredient with at least one meltable binder andopt. other additives, and either injection moulding or extruding and shaping the mxit. at 50-180 deg.C.. The binder is a solvent free polymer of N-vinylpyrrolidone (NVP) comprising 20-100 wt.% NVP and 0-80 wt.% of N- and/or O-contg. comonomers. The polymer contains no more than 3.5 wt.% H2O.At least when the mxit. has a glass temp. above 130 deg.C, the polymer must be produced by polymerisation in an organic solvent or by polymerisation in an aq. medium using an organic peroxide initiator. The mixt. contains no added thermoplasts which are sparingly soluble in gastric juices.

公开(公告)号：AT75941T

公开(公告)日：1992-05-15

申请号：AT89114814

申请日：1989-08-10

Applicant: BASF AG

Inventor： HORN DIETER DR ,  KRUEGER GOETZ DR ,  SPENGLER REINHARD DR

IPC: A61K9/14 ,  A61K9/16 ,  A61K31/52 ,  A61K47/24 ,  A61K47/26 ,  A61P11/08

公开(公告)号：DE3827362A1

公开(公告)日：1990-02-15

申请号：DE3827362

申请日：1988-08-12

Applicant: BASF AG

Inventor： HORN DIETER DR ,  KRUEGER GOETZ DR ,  SPENGLER REINHARD DR

IPC: A61K9/14 ,  A61K9/16 ,  A61K31/52 ,  A61K47/24 ,  A61K47/26 ,  A61P11/08

Abstract: A hydrophilic theophylline powder formulation consisting of (a) from 5 to 15% by weight of theophylline, (b) from 15 to 30% by weight of lechithin, (c) from 45 to 80% by weight of sugar, (d) from 0 to 5% by weight of a flow agent and (e) from 0 to 30% by weight of further additives, and a process for its preparation.